A cluster contribution to European life science innovation and competitiveness?

Genmab to Acquire Dutch biotech for USD 8 Billion

Danish pharmaceutical company Genmab has agreed to acquire Dutch firm Merus, a developer of cancer therapies, for USD 8 billion, equivalent to nearly SEK 75 billion.

Wegovy slog Mounjaro i studie om hjärtinfarkt

Under söndagen presenterade Novo Nordisk ny studiedata som pekar på att Wegovy kan minska risken för allvarliga kardiovaskulära händelser mer än Eli Lillys konkurrerade viktläkemedel Mounjaro.

KI-studie: Blodprov kan förutspå och utesluta framtida demens

Förekomsten av vissa biomarkörer i blodet kan förutsäga utvecklingen av demens upp tio år innan en faktisk diagnos ställs, enligt en ny studie vid Karolinska institutet.

Investment CEO: “The Nordics are outstanding in creating successful medtech companies”

in, which companies she believes in the most in the portfolio and why she accepted the new position.

Ny vd hos Segulah: ”Spännande att gå över till investerarsidan”

Susanna Francke Rodau är ny vd och partner i Segulah Medical Acceleration.

He takes over the chairmanship of Karolinska Development

Ben Toogood is appointed as the new chairman of Karolinska Developments.

GSK acquires oncology research company

GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.

Rise and Scantox cease conducting animal testing in Stockholm

Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs are high, and demand is weak”, says the division manager at Rise to Life Science Sweden.

Seminarier får svensk life science att blomstra: “Fyller rummet med rätt personer”

Minimala risker, maximal räckvidd. Genom ett unikt koncept hjälper nu Medicon Valley Alliance företag att skapa mötesplatser där rätt personer samlas – och intresset ökar.

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical companies are highlighted as a success factor. “Everyone has heard of Novo Nordisk, but these companies are unknown to people outside the industry despite being the golden vein of the life science sector,” says Anette Steenberg, CEO of the cluster organisation MVA.

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Innovative start-up helps doctors, scientists and industry balance coagulation risks

For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial for maintaining normal haemostasis.

Japanese pharma to buy US drugmaker for $2.4 bln

Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.

Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”

It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or whether they are indeed right (or wrong) for the current project, Anna Törner writes in a column.

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, Head of Unit at the Swedish Medical Products Agency, who continues to persistently spread her message: don’t postpone the transition.

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”

It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless different assignments later, Per Alfredsson, born and raised in Södertälje, is CEO of Astra Zeneca Sweden, which employs 7800 people in Södertälje, Stockholm and Gothenburg. “It was a very special feeling to be in charge of the entire organisation,” he says in an interview about his career and potential future blockbusters.

Sårvårdsbolag ansöker om rekonstruktion

Sårvårdsföretaget S2 Medical ställer tillfälligt in sina betalningar och ansöker om företagsrekonstruktion vid Linköpings tingsrätt.

Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell

Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Michael Linnell, project manager for Life Science Sweden’s event portfolio, a few short questions.

Bioarctic granted Japanese patent for Parkinson’s disease candidate

Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.

Uppsala-based company wins important patent dispute – but the decision is subject to appeal

A US district court has ruled in favour of Orexo in a dispute over the patent protecting the Swedish company’s drug Zubsolv, developed for treating patients with opioid addiction. However, the opposing party, the Indian company Sun, is not giving up and has filed an appeal.